EVGN vs. NKGN, ENLV, NRXP, THTX, MDAI, APRE, IINN, NUTX, NMTC, and CRTX
Should you be buying Evogene stock or one of its competitors? The main competitors of Evogene include NKGen Biotech (NKGN), Enlivex Therapeutics (ENLV), NRx Pharmaceuticals (NRXP), Theratechnologies (THTX), Spectral AI (MDAI), Aprea Therapeutics (APRE), Inspira Technologies Oxy B.H.N. (IINN), Nutex Health (NUTX), NeuroOne Medical Technologies (NMTC), and Cortexyme (CRTX). These companies are all part of the "medical" sector.
Evogene (NASDAQ:EVGN) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, community ranking, valuation, profitability, dividends and risk.
Evogene has higher revenue and earnings than NKGen Biotech.
NKGen Biotech has a net margin of 0.00% compared to Evogene's net margin of -423.39%. NKGen Biotech's return on equity of 0.00% beat Evogene's return on equity.
Evogene has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.
In the previous week, Evogene had 1 more articles in the media than NKGen Biotech. MarketBeat recorded 2 mentions for Evogene and 1 mentions for NKGen Biotech. Evogene's average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score.
Evogene presently has a consensus price target of $3.62, suggesting a potential upside of 448.89%. Given Evogene's higher probable upside, analysts clearly believe Evogene is more favorable than NKGen Biotech.
Evogene received 219 more outperform votes than NKGen Biotech when rated by MarketBeat users.
10.4% of Evogene shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 7.4% of Evogene shares are owned by company insiders. Comparatively, 20.0% of NKGen Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Evogene beats NKGen Biotech on 8 of the 13 factors compared between the two stocks.
Get Evogene News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
